• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用CRISPR/Cas9敲除ABC转运蛋白有助于在药物研发中可靠且准确地鉴定转运蛋白底物。

Knockout of ABC transporters by CRISPR/Cas9 contributes to reliable and accurate transporter substrate identification for drug discovery.

作者信息

Feng Dongyan, Zhong Guorui, Zuo Qingxia, Wan Yanbin, Xu Wanqing, He Changsheng, Lin Cailing, Huang Dongchao, Chen Feng, Huang Lizhen

机构信息

School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.

Bioinformatics Institute, Agency for Science, Technology, and Research (ASTAR), Singapore, Singapore.

出版信息

Front Pharmacol. 2022 Oct 28;13:1015940. doi: 10.3389/fphar.2022.1015940. eCollection 2022.

DOI:10.3389/fphar.2022.1015940
PMID:36386127
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9649518/
Abstract

It is essential to explore the relationship between drugs and transporters in the process of drug development. Strong background signals in nonhuman MDCK or LLC-PK1 cells and overlapping interference of inhibitors or RNAi in human Caco-2 cells mean that an ideal alternative could be to knock out specific transporter genes in Caco-2 cells. However, the application of gene knockout (KO) to Caco-2 cells is challenging because it is still inefficient to obtain rapidly growing Caco-2 subclones with double-allele KO through long-term monoclonal cultivation. Herein, CRISPR/Cas9, a low cost but more efficient and precise gene editing technology, was utilized to singly or doubly knockout the P-gp, BCRP, and MRP2 genes in Caco-2 cells. By combining this with single cell expansion, rapidly growing transporter-deficient subclones were successfully screened and established. Bidirectional transport assays with probe substrates and three protease inhibitors indicated that more reliable and detailed data could be drawn easily with these KO Caco-2 models. The six robust KO Caco-2 subclones could contribute to efficient drug transport research.

摘要

在药物研发过程中,探索药物与转运体之间的关系至关重要。非人类MDCK或LLC-PK1细胞中的强背景信号以及人类Caco-2细胞中抑制剂或RNAi的重叠干扰意味着,一个理想的替代方法可能是敲除Caco-2细胞中的特定转运体基因。然而,将基因敲除(KO)应用于Caco-2细胞具有挑战性,因为通过长期单克隆培养获得具有双等位基因敲除的快速生长的Caco-2亚克隆仍然效率低下。在此,利用CRISPR/Cas9这种低成本但更高效、精确的基因编辑技术,在Caco-2细胞中对P-gp、BCRP和MRP2基因进行单敲除或双敲除。通过将此与单细胞扩增相结合,成功筛选并建立了快速生长的转运体缺陷亚克隆。用探针底物和三种蛋白酶抑制剂进行的双向转运试验表明,利用这些敲除的Caco-2模型可以轻松得出更可靠、更详细的数据。这六个强大的敲除Caco-2亚克隆有助于高效的药物转运研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/a3dd3303e542/fphar-13-1015940-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/46c976a4e684/fphar-13-1015940-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/07fbebc89bb6/fphar-13-1015940-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/76004ceb9b76/fphar-13-1015940-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/55e8df2e58e9/fphar-13-1015940-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/02063660c89c/fphar-13-1015940-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/a3dd3303e542/fphar-13-1015940-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/46c976a4e684/fphar-13-1015940-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/07fbebc89bb6/fphar-13-1015940-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/76004ceb9b76/fphar-13-1015940-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/55e8df2e58e9/fphar-13-1015940-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/02063660c89c/fphar-13-1015940-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb1/9649518/a3dd3303e542/fphar-13-1015940-g006.jpg

相似文献

1
Knockout of ABC transporters by CRISPR/Cas9 contributes to reliable and accurate transporter substrate identification for drug discovery.利用CRISPR/Cas9敲除ABC转运蛋白有助于在药物研发中可靠且准确地鉴定转运蛋白底物。
Front Pharmacol. 2022 Oct 28;13:1015940. doi: 10.3389/fphar.2022.1015940. eCollection 2022.
2
Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.锌指核酸酶介导的基因敲除导致Caco-2细胞中P-糖蛋白、乳腺癌耐药蛋白(BCRP)和多药耐药相关蛋白2(MRP2)的转运活性丧失。
Drug Metab Dispos. 2015 Feb;43(2):199-207. doi: 10.1124/dmd.114.057216. Epub 2014 Nov 11.
3
Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.马兜铃酸I是乳腺癌耐药蛋白(BCRP)的底物,但不是P-糖蛋白或多药耐药相关蛋白2(MRP2)的底物。
J Ethnopharmacol. 2015 Aug 22;172:430-5. doi: 10.1016/j.jep.2015.07.011. Epub 2015 Jul 13.
4
Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.Caco-2 和 MDCK-MDR1 单层细胞中外排转运蛋白抑制剂的差异选择性:评估新化学实体与 P-糖蛋白、BCRP 和 MRP2 相互作用的策略。
J Pharm Sci. 2012 May;101(5):1888-97. doi: 10.1002/jps.23069. Epub 2012 Feb 22.
5
Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.拓展体外外排测定工具盒:经 CRISPR-Cas9 编辑的、人源 BCRP 表达完全而缺乏犬源 MDR1 的 MDCK 细胞系
J Pharm Sci. 2021 Jan;110(1):388-396. doi: 10.1016/j.xphs.2020.09.039. Epub 2020 Sep 29.
6
Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.犬 P-糖蛋白缺陷型 MDCK II 细胞系的特征鉴定和验证及其在外排底物筛选中的应用。
Pharm Res. 2020 Sep 11;37(10):194. doi: 10.1007/s11095-020-02895-9.
7
Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.通过质谱法定量 ABC 转运体及其对利伐沙班经转运体介导的药物相互作用的体外至体内预测的影响。
Eur J Pharm Biopharm. 2020 Mar;148:27-37. doi: 10.1016/j.ejpb.2020.01.002. Epub 2020 Jan 13.
8
A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.一种新型的肠道细胞培养模型,用于区分 P-糖蛋白和 BCRP 对伊马替尼等底物转运的相对贡献。
Mol Pharm. 2010 Oct 4;7(5):1618-28. doi: 10.1021/mp100040f. Epub 2010 Aug 11.
9
The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein.内源性乳腺癌耐药蛋白对 LLC-PK1 细胞中转染人 P-糖蛋白的人类 P-糖蛋白介导的转运试验的影响。
J Pharm Sci. 2019 Mar;108(3):1085-1089. doi: 10.1016/j.xphs.2018.10.012. Epub 2018 Oct 16.
10
Application and limitation of inhibitors in drug-transporter interactions studies.抑制剂在药物转运体相互作用研究中的应用与局限性
Int J Pharm. 2008 May 22;356(1-2):12-8. doi: 10.1016/j.ijpharm.2007.12.024. Epub 2007 Dec 24.

引用本文的文献

1
The impact of the ATP-binding cassette (ABC) transporter family on multidrug resistance in head and neck tumors.ATP结合盒(ABC)转运蛋白家族对头颈肿瘤多药耐药性的影响。
Mol Biol Rep. 2025 Feb 21;52(1):256. doi: 10.1007/s11033-025-10321-9.
2
Knockout Transporter Cell Lines to Assess Substrate Potential Towards Efflux Transporters.建立敲除转运体的细胞系以评估底物对外排转运体的潜在作用。
AAPS J. 2024 Jul 10;26(4):79. doi: 10.1208/s12248-024-00950-6.
3
Membrane transporters in drug development and as determinants of precision medicine.

本文引用的文献

1
Investigation of the Uptake and Transport of Two Novel Camptothecin Derivatives in Caco-2 Cell Monolayers.研究两种新型喜树碱衍生物在 Caco-2 细胞单层中的摄取和转运。
Molecules. 2022 Jun 7;27(12):3669. doi: 10.3390/molecules27123669.
2
Multidrug resistance-associated protein 2 (MRP2) is an efflux transporter of EGCG and its metabolites in the human small intestine.多药耐药相关蛋白 2(MRP2)是 EGCG 及其代谢物在人小肠中的外排转运体。
J Nutr Biochem. 2022 Sep;107:109071. doi: 10.1016/j.jnutbio.2022.109071. Epub 2022 May 27.
3
Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices.
药物开发中的膜转运体和精准医学的决定因素。
Nat Rev Drug Discov. 2024 Apr;23(4):255-280. doi: 10.1038/s41573-023-00877-1. Epub 2024 Jan 24.
抗HIV和抗HCV药物抑制P-糖蛋白介导的地高辛在Caco-2细胞系和人精密切割肠片中流出的效能评估。
Pharmaceuticals (Basel). 2022 Feb 18;15(2):242. doi: 10.3390/ph15020242.
4
Impact of the clinically approved Petasites hybridus extract Ze 339 on intestinal mechanisms involved in the handling of histamine.临床认可的款冬属杂种植物提取物 Ze 339 对涉及组胺处理的肠道机制的影响。
Biomed Pharmacother. 2022 Apr;148:112698. doi: 10.1016/j.biopha.2022.112698. Epub 2022 Feb 8.
5
Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.达布拉非尼抑制 ABCG2 和细胞色素 P450 同工酶;对联合抗癌治疗的潜在影响。
Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
6
Rifampicin Induces Gene, Protein, and Activity of P-Glycoprotein (ABCB1) in Human Precision-Cut Intestinal Slices.利福平诱导人精密切割肠切片中P-糖蛋白(ABCB1)的基因、蛋白质及活性。
Front Pharmacol. 2021 Jun 9;12:684156. doi: 10.3389/fphar.2021.684156. eCollection 2021.
7
Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling.基于 SVM 分类器和 PBPK 模型预测源于中药的天然产物的口服肝毒性剂量。
Arch Toxicol. 2021 May;95(5):1683-1701. doi: 10.1007/s00204-021-03023-1. Epub 2021 Mar 13.
8
siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects.小干扰RNA的特异性:RNA干扰机制及减少脱靶效应的策略。
Front Plant Sci. 2021 Jan 28;11:526455. doi: 10.3389/fpls.2020.526455. eCollection 2020.
9
P-Glycoprotein-Mediated Efflux Using a Rapidly Maturing Caco2 Clone (CLEFF4) in Only 5 Days without Requiring Modified Growth Medium.使用仅需 5 天即可快速成熟的 Caco2 克隆(CLEFF4),无需改良生长培养基,即可实现 P-糖蛋白介导的外排。
SLAS Discov. 2021 Jan;26(1):151-160. doi: 10.1177/2472555220942758. Epub 2020 Jul 24.
10
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy.膜嵌入药物外排ABC转运蛋白在癌症化疗中的作用。
Oncol Rev. 2020 Jul 6;14(2):448. doi: 10.4081/oncol.2020.448.